抗HCV新药sofosbuvir和ABT-450研究进展

Research progress of sofosbuvir and ABT-450,the newest direct-acting anti-HCV agents

长期以来,聚乙二醇干扰素α联合利巴韦林是治疗慢性丙型肝炎的标准疗法,但HCV基因1、4型患者的持续病毒学应答率仅为40%-50%,基因2、3、5、6型患者约为80%。所以,提高临床疗效成为临床医生最为关注的问题。近年来不断有新研发的小分子直接抗病毒药物（direct-acting antiviral agents,DAAs）问世,临床试验表明DAAs更具特异性和有效性,且疗程短,不良反应少。本文简要介绍抗HCV药物的发展历程以及2013年1月在《新英格兰医学杂志》上报道的2种最新药物sofosbuvir和ABT-450的临床试验结果,并展望未来抗HCV的临床研究方向。

Combination therapy with pegylated interferon o~ and ribavirin has been the standard of care for chronic hepatitis C for years. But sustained virological response rates in patients with HCV genotype 1, 4 and genotype 2, 3, 5, 6 are 40%-50% and about 80%, respectively. Therefore, how to improve clinical efficacy is the most important concern of clinical physicians. In recent years, several direct-acting antiviral agents （DAAs） have been developed, and clinical trials have shown that DAAs are characterized by greater specificity and effectiveness, shorter duration of treatment and fewer adverse reactions. The authors briefly introduce the development history of anti-HCV agents and the clinical efficacy of sofosbuvir and ABT-450, which were reported in the literatures published on New England Journal of Medicine in Jan. 2013, and point out the prospect of anti-HCV clinical research.